• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma.

作者信息

Herman Joseph M, Fan Katherine Y, Wild Aaron T, Wood Laura D, Blackford Amanda L, Donehower Ross C, Hidalgo Manuel, Schulick Richard D, Edil Barish H, Choti Michael A, Hruban Ralph H, Pawlik Timothy M, Cameron John L, Laheru Daniel A, Iacobuzio-Donahue Christine A, Wolfgang Christopher L

机构信息

Department of Radiation Oncology & Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.

出版信息

Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):458-9. doi: 10.1016/j.ijrobp.2013.06.2039.

DOI:10.1016/j.ijrobp.2013.06.2039
PMID:24074918
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3982289/
Abstract
摘要

相似文献

1
Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma.胰腺癌切除术后接受厄洛替尼联合辅助放化疗和化疗患者中Smad4状态与预后的相关性
Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):458-9. doi: 10.1016/j.ijrobp.2013.06.2039.
2
Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation.在接受辅助放化疗的胰腺癌患者中，Smad4缺失与局部和远处较高的复发率相关。
Pancreas. 2018 Feb;47(2):208-212. doi: 10.1097/MPA.0000000000000985.
3
SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.SMAD4 缺失与胰腺腺癌患者新辅助化疗加羟氯喹治疗的反应相关。
Clin Transl Sci. 2021 Sep;14(5):1822-1829. doi: 10.1111/cts.13029. Epub 2021 May 18.
4
Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy.重新定义胰腺癌的阳性切缘：对失败模式、长期生存和辅助治疗的影响。
Ann Surg Oncol. 2017 Nov;24(12):3674-3682. doi: 10.1245/s10434-017-6076-z. Epub 2017 Sep 5.
5
Can we move towards personalised pancreatic cancer therapy?我们能否迈向个性化胰腺癌治疗？
Expert Rev Gastroenterol Hepatol. 2014 May;8(4):335-8. doi: 10.1586/17474124.2014.893820. Epub 2014 Apr 4.
6
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.胰腺导管腺癌的遗传多样性与精准医学机遇
Gastroenterology. 2016 Jan;150(1):48-63. doi: 10.1053/j.gastro.2015.08.056. Epub 2015 Sep 15.
7
Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on operative outcome and pattern of recurrence.术前基于吉西他滨的放化疗治疗胰体尾导管腺癌：脾血管受累对手术结果及复发模式的影响
Surgery. 2015 Mar;157(3):484-95. doi: 10.1016/j.surg.2014.09.022. Epub 2014 Oct 16.
8
Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients.SMAD4 阴性胰腺腺癌患者组织学分级较差与生存预后较差相关。
J Surg Oncol. 2021 Feb;123(2):389-398. doi: 10.1002/jso.26279. Epub 2020 Nov 4.
9
The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.DPC4/SMAD4基因状态决定了切除的胰腺导管腺癌的复发模式和治疗结果：一项前瞻性队列研究。
Oncotarget. 2017 Mar 14;8(11):17945-17959. doi: 10.18632/oncotarget.14901.
10
Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma.围手术期红细胞输血对胰十二指肠切除术治疗导管腺癌后疾病复发和生存的影响。
Ann Surg Oncol. 2011 May;18(5):1327-34. doi: 10.1245/s10434-010-1476-3. Epub 2011 Jan 8.

引用本文的文献

1
Liquid biopsy in gallbladder carcinoma: Current evidence and future prospective.胆囊癌的液体活检：当前证据与未来展望。
J Liq Biopsy. 2024 Nov 26;6:100280. doi: 10.1016/j.jlb.2024.100280. eCollection 2024 Dec.
2
An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms.一种针对 EGFR/HER2 的偶联物通过不同的 SMAD4 介导机制使吉西他滨敏感和耐药的胰腺癌敏感化。
Nat Commun. 2022 Sep 20;13(1):5506. doi: 10.1038/s41467-022-33037-x.
3
Identification of Altered Genes in Gallbladder Cancer as Potential Driver Mutations for Diagnostic and Prognostic Purposes: A Computational Approach.鉴定胆囊癌中发生改变的基因作为用于诊断和预后目的的潜在驱动突变：一种计算方法。
Cancer Inform. 2020 May 25;19:1176935120922154. doi: 10.1177/1176935120922154. eCollection 2020.
4
Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer.原发性胰腺癌根治性切除术后孤立性局部区域复发患者的确定性放化疗及挽救性化疗
Cancer Manag Res. 2019 May 31;11:5065-5073. doi: 10.2147/CMAR.S202543. eCollection 2019.
5
Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.胰腺导管腺癌的基因组分析与个体化治疗之路：范围综述。
Cancer Treat Rev. 2019 May;75:27-38. doi: 10.1016/j.ctrv.2019.03.003. Epub 2019 Mar 22.
6
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine.在个性化医学时代，用 PI3K 通路抑制剂对抗胰腺癌。
Gut. 2019 Apr;68(4):742-758. doi: 10.1136/gutjnl-2018-316822. Epub 2018 Nov 5.
7
Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation.在接受辅助放化疗的胰腺癌患者中，Smad4缺失与局部和远处较高的复发率相关。
Pancreas. 2018 Feb;47(2):208-212. doi: 10.1097/MPA.0000000000000985.
8
Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC.对于局部晚期胰腺癌（LAPC），采用调强放疗（IMRT）技术分15至28次递增剂量比三维适形放疗（3DCRT）的标准剂量耐受性更好。
Adv Radiat Oncol. 2017 Mar 18;2(3):403-415. doi: 10.1016/j.adro.2017.02.004. eCollection 2017 Jul-Sep.
9
TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma.TAp73缺失有利于不依赖Smad的TGF-β信号传导，该信号传导驱动胰腺导管腺癌中的上皮-间质转化。
Cell Death Differ. 2016 Aug;23(8):1358-70. doi: 10.1038/cdd.2016.18. Epub 2016 Mar 4.
10
Pancreatic cancer and SBRT: A new potential option?胰腺癌与立体定向体部放疗：一种新的潜在选择？
Rep Pract Oncol Radiother. 2015 Sep-Oct;20(5):377-84. doi: 10.1016/j.rpor.2015.05.008. Epub 2015 Jun 28.

本文引用的文献

1
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.卡培他滨、吉西他滨和奥沙利铂联合治疗局部晚期（T4）胰腺腺癌序贯卡培他滨放化疗的 II 期临床试验：Smad4（Dpc4）免疫染色与疾病进展模式的相关性。
J Clin Oncol. 2011 Aug 1;29(22):3037-43. doi: 10.1200/JCO.2010.33.8038. Epub 2011 Jun 27.
2
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.SMAD4基因突变与胰腺癌的不良预后相关。
Clin Cancer Res. 2009 Jul 15;15(14):4674-9. doi: 10.1158/1078-0432.CCR-09-0227. Epub 2009 Jul 7.
3
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.原发性癌的DPC4基因状态与胰腺癌患者的复发模式相关。
J Clin Oncol. 2009 Apr 10;27(11):1806-13. doi: 10.1200/JCO.2008.17.7188. Epub 2009 Mar 9.
4
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.DPC4，一种位于人类18号染色体q21.1区域的候选抑癌基因。
Science. 1996 Jan 19;271(5247):350-3. doi: 10.1126/science.271.5247.350.